BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has appointed Timothy P. Walbert, former chairman, president and chief executive officer of Horizon Therapeutics, to the ...
Oppenheimer upgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a market perform rating to an outperform rating in a research note published on Monday morning, MarketBeat ...
Hosted on MSN13h
Oppenheimer Upgrades BioMarin Pharmaceutical (BMRN)Fintel reports that on February 24, 2025, Oppenheimer upgraded their outlook for BioMarin Pharmaceutical (NasdaqGS:BMRN) from ...
TipRanks on MSN15h
BioMarin Expands Board with New Independent DirectorBioMarin Pharmaceutical’s Board of Directors expanded from eleven to twelve members, appointing Timothy P. Walbert as an independent director effective Feb ...
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great ...
The average of price targets set by Wall Street analysts indicates a potential upside of 40.5% in BioMarin (BMRN). While the effectiveness of this highly sought-after metric is questionable, the ...
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback